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Metabolic syndrome is a growing health problem worldwide. It is
therefore imperative to develop new strategies to treat this
pathology. In the past years, the manipulation of NAD
+ metabo-
lism has emerged as a plausible strategy to ameliorate metabolic
syndrome. In particular, an increase in cellular NAD
+ levels has
beneﬁcial effects, likely because of the activation of sirtuins. Pre-
viously, we reported that CD38 is the primary NAD
+ase in mam-
mals. Moreover, CD38 knockout mice have higher NAD
+ levels
and are protected against obesity and metabolic syndrome. Here,
we show that CD38 regulates global protein acetylation through
changes in NAD
+ levels and sirtuin activity. In addition, we char-
acterize two CD38 inhibitors: quercetin and apigenin. We show
that pharmacological inhibition of CD38 results in higher intra-
cellular NAD
+ levels and that treatment of cell cultures with api-
genin decreases global acetylation as well as the acetylation of
p53 and RelA-p65. Finally, apigenin administration to obese mice
increases NAD
+ levels, decreases global protein acetylation, and
improves several aspects of glucose and lipid homeostasis. Our
results show that CD38 is a novel pharmacological target to treat
metabolic diseases via NAD
+-dependent pathways. Diabetes
62:1084–1093, 2013
O
besity is a disease that has reached epidemic
proportions in developed and developing coun-
tries (1–3). In the U.S., .60% of the population is
overweight (1,3,4). Obesity is a feature of meta-
bolic syndrome, which includes glucose intolerance, insulin
resistance, dyslipidemia, and hypertension. These patholo-
gies are well-documented risk factors for cardiovascular
disease, type 2 diabetes, and stroke (4). It is therefore im-
perative to envision new strategies to treat metabolic syn-
drome and obesity.
Recently, the role of NAD
+ as a signaling molecule in
metabolism has become a focus of intense research. It was
shown that an increase in intracellular NAD
+ levels in
tissues protects against obesity (5,6), metabolic syndrome,
and type 2 diabetes (5–7). Our group was the ﬁrst to dem-
onstrate that an increase in NAD
+ levels protects against
high-fat diet–induced obesity, liver steatosis, and metabolic
syndrome (5). This concept was later expanded by others
using different approaches, including inhibition of poly-ADP-
ribose polymerase (PARP)1 (6) and stimulation of NAD
+
synthesis (7).
The ability of NAD
+ to affect metabolic diseases seems
to be mediated by sirtuins (8). This family of seven NAD
+-
dependent protein deacetylases, particularly SIRT1, SIRT3,
and SIRT6, has gained signiﬁcant attention as candidates
to treat metabolic syndrome and obesity (9). Sirtuins use
and degrade NAD
+ as part of their enzymatic reaction (8),
which makes NAD
+ a limiting factor for sirtuin activity (9).
In particular, silent mating information regulation 2 ho-
molog 1 (SIRT1) has been shown to deacetylate several
proteins, including p53 (10), RelA/p65 (11), PGC1-a (12),
and histones (13), among others. In addition, increased
expression of SIRT1 (14), increased SIRT1 activity (15),
and pharmacological activation of SIRT1 (16) protect mice
against liver steatosis and other features of metabolic
syndrome when mice are fed a high-fat diet. Given the
beneﬁcial consequences of increased SIRT1 activity, great
efforts are being directed toward the development of
pharmacological interventions aimed at activating SIRT1.
We previously reported that the protein CD38 is the
primary NAD
+ase in mammalian tissues (17). In fact, tis-
sues of mice that lack CD38 contain higher NAD
+ levels
(17,18) and increased SIRT1 activity compared with wild-
type mice (5,17). CD38 knockout mice are resistant to
high-fat diet–induced obesity and other aspects of meta-
bolic disease, including liver steatosis and glucose in-
tolerance, by a mechanism that is SIRT1 dependent (5).
These multiple lines of evidence suggest that pharmaco-
logical CD38 inhibition would lead to SIRT1 activation
through an increase in NAD
+ levels, resulting in beneﬁcial
effects on metabolic syndrome.
Recently, it was shown that in vitro, CD38 is inhibited by
ﬂavonoids, including quercetin (19). Flavonoids are naturally
occurring compounds present in a variety of plants and
fruits (20). Among them, quercetin [2-(3,4-dihydroxyphenyl)-
3,5,7-trihydroxy-4H-chromen-4-one] and apigenin [5,7-
dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one] have
b e e ns h o w nt oh a v eb e n e ﬁcial effects against cancer (21–24).
In fact, apigenin and quercetin ameliorate atherosclerosis (25)
and reduce inﬂammation (26–28). However, the mechanisms
of action of ﬂavonoids remain largely unknown. We hypoth-
esized that the effect of some ﬂavonoids in vivo may occur
through inhibition of CD38 and an increase in NAD
+ levels in
tissues, which lead to protection against metabolic syndrome.
Here, we show that CD38 expression and activity regu-
late cellular NAD
+ levels and global acetylation of proteins,
including SIRT1 substrates. We conﬁrmed that quercetin
is a CD38 inhibitor in vitro and in cells. Importantly, we
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ORIGINAL ARTICLEdemonstrate that apigenin is a novel inhibitor of CD38
in vitro and in vivo. Treatment of cells with apigenin or
quercetin inhibits CD38 and promotes an increase in in-
tracellular NAD
+ levels. An increased NAD
+ level decrea-
ses protein acetylation through sirtuin activation. Finally,
treatment of obese mice with apigenin results in CD38
inhibition, higher NAD
+ levels in the liver, and a decrease
in protein acetylation. Apigenin treatment improves glu-
cose homeostasis, glucose tolerance, and lipid metabolism
in obese mice. Our results clearly demonstrate that CD38
is a novel therapeutic target for the treatment of metabolic
diseases and that apigenin and quercetin as well as other
CD38 inhibitors may be used to treat metabolic syndrome.
RESEARCH DESIGN AND METHODS
Reagents and antibodies. All reagents and chemicals were from Sigma-
Aldrich. Antibodiesforhuman SIRT1,mouse SIRT1,p65,acetylatedp53 (K382),
phosphorylated AMP-activated protein kinase (AMPK) (Thr172), AMPK, and
acetyl-lysine were from Cell Signaling Technology. Antibody against Nampt
was from Bethyl Laboratories. Anti-human CD38 antibody was from R&D
Biosystems, and anti-mouse CD38 was from Epitomics.
Cell culture. A549 cells were kept in RPMI 1640 media supplemented with 10%
FBS and penicillin/streptomycin (Invitrogen). Primary CD38 wild-type and
knockoutmouseembryonicﬁbroblasts (MEFs)werekeptinDulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FBS, penicillin/streptomycin, and glu-
tamine. Primary MEFs were isolated form embryos (E18) from wild-type and
CD38 knockout mice. Primary MEFs were used between passages 2 and 5. 293T
and hepatocellular carcinoma (Hep)G2 cells were kept in Dulbecco’sm o d i ﬁed
Eagle’s medium supplemented with 10% FBS and penicillin/streptomycin.
Overexpression and small interfering RNA. Full-length human CD38 was
subcloned into a modiﬁed pIRES2–enhanced green ﬂuorescent protein vector.
For overexpression, 293T cells were transfected for 48 h with Lipofectamine
2000 (Invitrogen) following the manufacturer’s instructions.
For CD38 knockdown experiments, probe no. 2 of a TriFECTa kit against
human CD38 was used (cat. no. HSC.RNAI.N001775.12.2; IDT). A549 cells
were transfected with 40 nmol small interfering RNA (siRNA) duplex using
Lipofectamine 2000 according to the manufacturer’s instructions.
Determination of CD38 activity. Determination of CD38 activity in cells and
tissues was performed as previously described (17). In vitro CD38 activity was
measured using 0.1 unit of recombinant human CD38 (R&D Systems) in 0.25
mol/L sucrose and 40 mmol/L Tris-HCl (pH 7.4). The reaction was started
by addition of 0.2 mmol/L substrate. Nicotinamide 1,N
6-ethenoadenine di-
nucleotide was used to determine NAD
+ase activity and nicotinamide guanine
dinucleotide to determine cyclase activity. CD38 activity was expressed as
arbitrary ﬂuorescent units per minute (AFU/min).
NAD
+ quantiﬁcation. NAD
+ extraction and quantiﬁcation was performed as
previously described (17). In brief, cells were lysed by sonication in ice-cold
10% trichloroacetic acid, and then the trichloroacetic acid was extracted with
two volumes of an organic phase consisting of 1,1,2-trichloro-1,2,2-triﬂuro-
ethane and trioctylamine. NAD
+ concentration was measured by means of an
enzymatic cycling assay (18).
FIG. 1. CD38 overexpression decreases NAD
+ and promotes protein acetylation in cells. 293T cells were transfected with empty vector or human
CD38-coding vector. After 48 h, cells were harvested, and NAD
+ase activity (A), ADP-ribosyl-cyclase activity (B), and total intracellular NAD
+
levels (C) were measured in cell lysates. *P < 0.05, n =3 .D: Western blot for CD38 in 293T cells transfected with empty vector or with human
CD38. E: Western blot showing total protein acetylation in cells transfected with empty vector or with human CD38. Anti–acetylated (Ac) lysine
antibody was used. Red arrows highlight the main bands that showed variations in intensity. F: Intensity proﬁle of the Western blot shown in E.
Western blots were scanned and intensity proﬁle was obtained using ImageJ. Red arrows correspond with intensity of the same bands shown in E.
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rimetric assay (Enzo) as previously described (15). One unit of human
recombinant SIRT1 was incubated with different concentrations of apigenin
plus 100 mmol/L Fluor-de-Lys p53 tetra peptide and 100 mmol/L NAD
+.F l u o r -
de-Lys developer was prepared according to the manufacturer’s recom-
mendations and added to the reactions for 1 h. Fluorescence was read with an
excitation of 360 nm and emission at 460 nm.
Mouse studies. All mice used in this study were maintained in the Mayo Clinic
Animal facility. All experimental protocols were approved by the institutional
animal care and use committee at Mayo Clinic (protocol no. A33209), and all
studies wereperformedaccordingtothemethodsapprovedintheprotocol.For
generation of obese mice, twelve 20-week-old C57BL/6 mice were placed on
a high-fat diet (AIN-93G, modiﬁed to provide 60% of calories from fat; Dyets) ad
libitum for 4 weeks. Body weight was recorded weekly. After 4 weeks of high-
fat diet, mice were randomly divided in two groups and injected daily with 100
mg/kg i.p. apigenin or vehicle for 7 consecutive days while remaining on the
high-fat diet. During the treatments, food intake and body weight were mon-
itored daily. There was no difference in these parameters between groups. For
theglucose tolerance experiments,micewerehousedfor24hwithout food,but
with water ad libitum, and challenged with one dose of 1.5 g/kg i.p. dextrose.
Area under the curve was calculated by the net incremental method (with
baseline) and presented as incremental area under the curve.
Gene expression analysis. RNA from ﬂash-frozen liver tissue was extracted
with an RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.
cDNA was synthesized with the iSCRIP cDNA synthesis kit (BioRad) using
600 ng RNA. Quantitative RT-PCR reactions were performed using 1 mmol/L
primers and LightCycler 480 SYBR Green Master (Roche) on a LightCycler 480
detection system (Roche). Calculations were performed by a comparative
method (2-DCT) using 18S rRNA as an internal control. Primers were designed
using the IDT software, and the primer sequences were as follows: long-chain
acyl-CoA dehydrogenase (LCAD), forward (Fw) GGTGGAAAACGGAAT
GAAAGG, reverse (Rv) GGCAATCGGACATCTTCAAAG; medium-chain acyl-CoA
dehydrogenase (MCAD), Fw TGTTAATCGGTGAAGGAGCAG, Rv CTATCCA
GGGCATACTTCGTG; CPT1a, Fw AGACAAGAACCCCAACATCC, Rv CAA
AGGTGTCAAATGGGAAGG; and 18S, Fw CGGCTACCACATCCAAGGAA, Rv
GCTGGAATTACCGCGGCT.
Lipid treatment. Cells were incubated with a mixture of oleic acid and pal-
mitic acid in a 2:1 ratio in culture media supplemented with 1% fatty acid–free
BSA (Sigma-Aldrich). Lipids were used at concentrations shown to induce
steatosis but not apoptosis (15). Incubations with lipids were performed for
16–24 h.
Statistics. Values are presented as means 6 SEM of three to ﬁve experiments
unless otherwise indicated. The signiﬁcance of differences between means
was assessed by ANOVA or two-tailed Student t test. A P value ,0.05 was
considered signiﬁcant.
RESULTS
CD38 overexpression decreases NAD
+ and promotes
protein acetylation. We have previously shown that
CD38 is the primary NAD
+ase in mammalian tissues (17).
FIG. 2. CD38 downregulation increases NAD
+ and decreases protein acetylation in cells. A549 cells were transfected with a scrambled siRNA
(control siRNA) or human CD38 siRNA. After 72 h, cells were harvested and NAD
+ase activity (A), ADP-ribosyl-cyclase activity (B), and total
intracellular NAD
+ levels (C) were measured from cell lysates. *P < 0.05, n =3 .D: Western blot showing total protein acetylation in cells
transfected with control siRNA or with human CD38 siRNA. Anti–acetylated (Ac) lysine antibody was used. Red arrows highlight the main bands
that showed variations in intensity. E: Intensity proﬁle of the Western blot shown in D. Western blots were scanned and intensity proﬁle was
obtained using Image J. Red arrows correspond with intensity of the same bands showed in D. F–H: Primary MEFs were puriﬁed and cultured from
wild-type (WT) and CD38 knockout (KO) mice. F: Intracellular NAD
+ levels (*P < 0.05, n =3 ) .G: Western blot from wild-type and CD38 knockout
MEFs showing total protein acetylation in these cells. H: Representative Western blot in wild-type and CD38 knockout MEFs. Acetylated RelA/p65
(K310), total RelA/p65, SIRT1, CD38, and actin antibodies were used.
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+ levels in multi-
ple tissues (5,17). To further characterize the role of CD38
in the regulation of NAD
+-dependent cellular events, we
studied the effect of CD38 manipulation in cells. We found
that cells that overexpress CD38 show a signiﬁcant in-
crease in NAD
+ase and ADP ribosyl cyclase activities
(Fig. 1A and B) and a consistent decrease in intracellular
NAD
+ levels (Fig. 1C). Interestingly, we found that over-
expression of CD38 also led to an increase in global pro-
tein acetylation (Fig. 1E). The pattern of acetylated
proteins was analyzed by plotting an intensity proﬁle of the
lanes in the Western blots (Fig. 1F). It is worth noting that
CD38 overexpression promotes changes in the level of
acetylation of several proteins (red arrows in Fig. 1E and
F), while other bands remain unchanged. This is consistent
with the fact that only sirtuin deacetylases depend on
NAD
+ for their activity (8); histone deacetylases of classes
I and II have a different enzymatic mechanism that does
not require NAD
+ (29).
CD38 downregulation increases NAD
+ and decreases
protein acetylation. Next, we examined whether CD38
downregulation promotes the opposite effect on cellular
NAD
+ levels and global protein acetylation. This is of key
relevance, since we (5) and other investigators (6,7) have
shown that an increase in intracellular NAD
+ levels pro-
tects against metabolic diseases and aging. We transfected
cells with control or CD38 siRNA. Cells treated with CD38
siRNA had decreased NAD
+ase and ADP ribosyl-cyclase
activities (Fig. 2A and B) and a signiﬁcant increase in in-
tracellular NAD
+ levels (Fig. 2C), consistent with the di-
minished CD38 NAD
+ase activity. Moreover, the increase
in NAD
+ levels was accompanied by a decrease in global
protein acetylation (Fig. 2D and E). Finally, we isolated
primary MEFs from wild-type and CD38 knockout mice
and measured NAD
+ levels and protein acetylation. We
found that CD38 knockout MEFs have increased NAD
+
levels (Fig. 2F) and decreased global protein acetylation
(Fig. 2G). We also analyzed p65/RelA acetylation at K310,
a site that is an accepted target for cellular SIRT1 activity
(7,11). We found that CD38 knockout MEFs show no de-
tectable p65/RelA (K310) acetylation compared with wild-
type cells, despite having similar total p65/RelA protein
(Fig. 2H) and similar SIRT1 levels. This indicates that
SIRT1 activity is increased in the CD38 knockout MEFs.
Apigenin and quercetin inhibit CD38 activity in vitro.
By use of high-throughput analysis to search for inhibitors
of CD38, we found that several ﬂavonoids, including
quercetin and apigenin, inhibit CD38 in vitro. The complete
screen will be published elsewhere. Recently, Kellenberger
et al. (19) also published a list of ﬂavonoids that act as
CD38 inhibitors in vitro, many of which were also con-
ﬁrmed by our analysis. Quercetin was one of the com-
pounds found by Kellenberger et al. (19) to inhibit CD38 in
vitro. Apigenin, however, was demonstrated to be a novel
CD38 inhibitor. We proceeded to further characterize
these compounds in vitro and in cells.
The effect of apigenin and quercetin on CD38 activity in
vitro was studied using the soluble ectodomain of human
CD38 (17). We found that apigenin (Fig. 3A) inhibits in
vitro CD38 activity with a half-maximal inhibitory con-
centration (IC50) of 10.3 6 2.4 mmol/L for the NAD
+ase
activity and an IC50 of 12.8 6 1.6 mmol/L for the ADP-
ribosyl-cyclase activity (Fig. 3B and C). In vitro, quercetin
(Fig. 3D) inhibits CD38 NAD
+ase activity with an IC50 of
FIG. 3. The ﬂavonoids apigenin and quercetin inhibit CD38 activity in vitro.A : Chemical structure of apigenin. B and C: In vitro NAD
+ase (B) and
ADP-ribosyl-cyclase (C) activity using human recombinant-puriﬁed CD38 and different concentrations of apigenin. D: Chemical structure of
quercetin. E and F: In vitro CD38 NAD
+ase activity (E) and ADP-ribosyl-cyclase activity (F) using human recombinant-puriﬁed CD38 and different
concentrations of apigenin. In all the measurements, compounds were used in the 0.5–100 mmol/L concentration range. Each measurement was
done by triplicate. Data points were ﬁtted to a standard competitive inhibition curve using a nonlinear regression program (GraphPad Prism) to
yield the IC50 value.
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tivity with an IC50 of 15.6 6 3.5 mmol/L (Fig. 3F).
CD38 inhibition by quercetin and apigenin increases
NAD
+ levels in cells. Although several ﬂavonoids can
inhibit puriﬁed recombinant CD38 in vitro (19), it is not
known what effects these compounds have in cells. First,
we measured the effect of quercetin on endogenous cel-
lular CD38 activity. Inhibition of CD38 activity by quercetin
in cells (IC50 =1 6 . 46 1.8 mmol/L) resembles the effect on
the recombinant protein (Fig. 4A). Furthermore, we found
that quercetin promotes an increase in intracellular NAD
+
in a dose-dependent manner (Fig. 4B). To further conﬁrm
this effect, we incubated cells in PBS and measured in-
tracellular NAD
+ levels over time. We found that in un-
treated cells, NAD
+ levels decrease with time (Fig. 4C),
probably as a result of the removal of NAD
+ precursors
from the culture media. However, when the cells were
treated with quercetin, NAD
+ levels were stable over time,
suggesting that inhibition of CD38 is enough to maintain
intracellular NAD
+ levels in the absence of NAD
+ pre-
cursors. Finally, in order to conﬁrm that the effect of
quercetin on cellular NAD
+ levels was dependent on CD38,
we measured NAD
+ after incubation with quercetin in
wild-type and CD38 knockout MEFs. We found that quer-
cetin promotes an increase in NAD
+ in the wild-type MEFs
but does not further increase NAD
+ levels in CD38
knockout MEFs (Fig. 4D), indicating that the effect of
quercetin on NAD
+ levels is CD38 dependent.
Apigenin also inhibits CD38 activity in cells (Fig. 5A). In
fact, inhibition of cellular CD38 was very similar to that
observed with the puriﬁed recombinant protein (IC50 =
14.8 6 2.2 mmol/L in cells and 10.3 6 2.4 mmol/L in vitro).
Apigenin treatment increased NAD
+ levels in cells in
a dose-dependent manner (Fig. 5B) and protected against
NAD
+ depletion when cells were incubated in PBS (Fig.
5C). Furthermore, treatment of CD38 knockout MEFs with
apigenin had no effect on NAD
+ levels (Fig. 5D), indicating
that the effect of apigenin on NAD
+ levels is mediated by
CD38. Interestingly, we found that treatment of wild-type
MEFs with apigenin decreased acetylation of RelA/p65
(Fig. 5E). However, in the CD38 knockout MEFs, RelA/p65
acetylation levels were undetectable in the control, and
therefore we could not determine the effect of apigenin
(Fig. 5E). These results are consistent with the effect of
apigenin in intracellular NAD
+ levels in these cells (Fig.
5D). Quercetin has been shown to activate SIRT1 in vitro
(30), suggesting that it may activate SIRT1 activity by
two different mechanisms. To rule out a possible direct
effect of apigenin on SIRT1 activity, we measured in
vitro recombinant SIRT1 activity in the presence of dif-
ferent concentrations of apigenin. We observed that
apigenin does not activate SIRT1 directly (Fig. 5F).
Combined, these results clearly demonstrate that api-
genin inhibits CD38 in cells and by doing so promotes an
increase in NAD
+ levels that stimulates NAD
+-dependent
deacetylases.
FIG. 4. CD38 inhibition by quercetin increases NAD
+ levels in cells. A: Endogenous CD38 NAD
+ase activity was measured in protein lysates from
A549 cells. Quercetin was used in the 0.5–100 mmol/L concentration range. Each measurement was done in triplicate. Data points were ﬁtted to
a standard competitive inhibition curve using a nonlinear regression program (GraphPad Prism) to yield the IC50 value. B: NAD
+ dose-response
curve in A549 cells treated with quercetin. Cells were incubated with quercetin for 6 h before NAD
+ extraction. *P < 0.05, n =3 .C: NAD
+ time
course in A549 cells incubated in PBS (●) or in PBS plus quercetin (50 mmol/L) (■). *P < 0.05, n =3 .D: Intracellular NAD
+ levels in wild-type
(WT) and CD38 knockout (KO) MEFs treated with vehicle (control) (■) or with quercetin (50 mmol/L) (□) for 6 h. NAD
+ levels were expressed as
percent of change with respect to the control for both cells. Total NAD
+ levels were signiﬁcantly higher in CD38 knockout MEFs. (See Fig. 2F.)
*P < 0.05, n =3 .
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+ and
decreases protein acetylation in mice. Apigenin and
quercetin have been shown to ameliorate atherosclerosis
in mice (25) and to protect against lipid accumulation in
cells (25). However, the mechanism of action has not been
elucidated. In fact, while most ﬂavonoids activate AMPK,
which could explain some of the metabolic effects ob-
served, apigenin is a very poor AMPK activator (25).
Based on the results obtained in cells, we tested whether
apigenin inhibits CD38 in vivo using a model of high-fat
diet–induced obesity (5,15). We fed adult mice a high-fat
diet for 4 weeks. After, we divided the mice randomly in
two groups. Each group was injected daily with apigenin
(100 mg/kg) or vehicle (DMSO) for a week. We found that
mice that had been injected with apigenin had decreased
CD38 activity in the liver (Fig. 6A), which correlated with
an increase in hepatic NAD
+ levels compared with control
mice (Fig. 6B). We then examined whether the apigenin
treatment had an effect on the level of expression of sev-
eral proteins involved in NAD
+ metabolism. As shown in
Fig. 6C, we found no signiﬁcant differences in the ex-
pression of CD38, SIRT1, or Nampt, the primary regulator
of the NAD
+ salvage pathway. Furthermore, we did not see
any changes in phosphorylation or total levels of AMPK
(Fig. 6C). However, when we analyzed the liver samples
using an acetyl-lysine antibody, we found that the apigenin
treatment resulted in a statistically signiﬁcant decrease in
global acetylation of proteins (Fig. 6D and E).
To determine the relevance of SIRT1 in the deacetyla-
tion of proteins triggered by apigenin treatment, we used
human HepG2 cells: a well-accepted cellular model for
studying hepatic cellular signaling (15,25,31). We found
that treatment with apigenin decreases total protein acet-
ylation—an effect that is lost in the presence of the
SIRT1 inhibitor EX527 (Fig. 6F). Furthermore, treatment
of HepG2 cells with apigenin decreased acetylation of p53
at K382 and also of RelA/p65 at K310: sites that are
deacetylated by SIRT1 (Supplementary Fig. 1). This effect
was reverted when cells were also incubated with the
sirtuin inhibitor nicotinamide (Supplementary Fig. 1).
Taken together, these results show that apigenin inhibits
CD38 in vivo and is associated with increased NAD
+ and
decreased protein acetylation, likely through the activation
of SIRT1.
CD38 inhibition by apigenin improves glucose
homeostasis in vivo and promotes fatty acid oxidation
in the liver. Finally, we tested whether apigenin protects
against high-fat diet–induced hyperglycemia. We found that
after 4 days of treatment, the mice treated with apigenin had
signiﬁcantly lower blood glucose levels compared with the
control mice (Fig. 7A). Fasting blood glucose levels were also
signiﬁcantly lower after 1 week of treatment with apigenin
(Fig. 7B). Moreover, we found that 1 week of treatment with
apigenin was enough to improve glucose homeostasis in the
mice (Fig. 7C and D). SIRT1 activation promotes fatty acid
oxidation in the liver by inducing the expression of several
FIG. 5. CD38 inhibition by apigenin increases NAD
+ and decreases protein acetylation in cells. A: Endogenous CD38 NAD
+ase activity was mea-
sured in protein lysates from A549 cells. Apigenin was used in the 2.5–100 mmol/L concentration range. Each measurement was done in triplicate.
Data points were ﬁtted to a standard competitive inhibition curve using a nonlinear regression program (GraphPad Prism) to yield the IC50 value.
B: NAD
+ dose-response curve in A549 cells treated with apigenin. Cells were incubated with apigenin for 6 h before NAD
+ extraction. C: NAD
+ time
course in A549 cells incubated in PBS (●) or in PBS plus 25 mmol/L apigenin (■)( * P < 0.05, n =3 ) .D: Intracellular NAD
+ levels in wild-type (WT)
and CD38 knockout (KO) MEFs treated with vehicle (control) (■) or with apigenin (25 mmol/L) (□) for 6 h. NAD
+ levels were expressed as
percent change with respect to the control for both cells. Total NAD
+ levels were signiﬁcantly higher in CD38 knockout MEFs. (See Fig. 2F.) *P <
0.05, n =3 .E: Western blot of wild-type and CD38 knockout MEFs that were treated with vehicle or apigenin as described in D. Samples were
immunoblotted for acetylated (Ac)-p65 (K310), total p65, CD38, SIRT1, and actin. F: In vitro SIRT1 activity using recombinant-puriﬁed human
SIRT1. SIRT1 activity was measured in the presence of different concentrations of apigenin (0–100 mmol/L). Activity was determined in the linear
portion of the reaction.
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(32). In fact, SIRT1 activation in the liver prevents liver
steatosis (5,14,15). Mice treated with apigenin had in-
creased expression of the enzymes MCAD and LCAD in
the liver (Fig. 8A), suggesting that apigenin treatment en-
hanced fatty acid oxidation. We conﬁrmed these data by
measuring total triglyceride content in the liver. Indeed,
we found that the mice treated with apigenin had lower
triglyceride levels in the liver compared with control mice
(Fig. 8B), showing that apigenin promotes hepatic lipid
oxidation. To further conﬁrm this ﬁnding, we measured
lipid accumulation in cells, using an in vitro model of he-
patic steatosis (15). We found that apigenin decreases lipid
accumulation in cells and that this effect was completely
blocked by the SIRT1 inhibitor EX527 (Fig. 8C). Together,
these results show that inhibition of CD38 by apigenin, and
perhaps by other ﬂavonoids, constitutes a pharmacologi-
cal approach to activate sirtuins and treat high-fat diet–
induced metabolic disorders. Furthermore, our results
point to CD38 as a novel pharmacological target to treat
metabolic diseases.
DISCUSSION
The alarming expansion of metabolic diseases has trig-
gered a considerable effort in the development of phar-
macological strategies to prevent and treat them. In this
regard, the study of sirtuins and speciﬁcally SIRT1 has
become of great relevance due to the many beneﬁcial
effects of their action (8,9). In fact, how to achieve SIRT1
activation in vivo is a subject of intense investigation. One
of the strategies to achieve such activation has been the
use of drugs that directly target SIRT1. Resveratrol (16)
and SRT1720 (33) are two of the early SIRT1-activating
compounds that improve metabolism and protect against
metabolic disorders, although there is a debate about their
mechanism of action (34–36). Another mechanism to
achieve SIRT1 activation in vivo is to raise intracellular
levels of NAD
+ either by increased synthesis or diminished
degradation (5–7,18). Previously, we have shown that the
enzyme CD38 is the principal regulator of intracellular
NAD
+ levels in mammalian tissues (17). In fact, we were
the ﬁrst to show that increasing NAD
+ levels by deletion of
FIG. 6. CD38 inhibition by apigenin increases NAD
+ and decreases protein acetylation in vivo.A –E: Mice were fed a high-fat diet (HFD) for 4 weeks
and then split in two groups. One group was injected with apigenin (100 mg/kg i.p.) and the other with vehicle (DMSO) with a single dose daily for 1
week. A: CD38 activity in the liver at the end of the treatment with apigenin (*P < 0.05, n = 6 animals per group). B: NAD
+ levels in the liver after
the treatment (*P < 0.05, n = 6 animals per group). C: At the end of the treatment, liver samples were obtained and immunoblotted for CD38,
phosphorylated (p)-AMPK (Thr172), AMPK, SIRT1, Nampt, and actin. D: Liver samples were immunoblotted for global acetylation of proteins
using an anti–acetylated (Ac) lysine (Lys) antibody. Western blots were scanned and an intensity proﬁle was obtained using Image J. The area
under the curve is shown. (*P < 0.05, n = 3 per group.) F: Human HepG2 cells were incubated with vehicle (DMSO), apigenin (25 mmol/L), or
apigenin plus EX527 (10 mmol/L) for 6 h. Cell lysates were immunoblotted for acetylated lysine to determine total protein acetylation levels (left
panel). The intensity proﬁle of the Western blot was obtained using Image J (right panel).
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activation (5). Other research groups later conﬁrmed the
importance of NAD
+ in the prevention of metabolic dis-
eases. Yoshino et al. (7) showed that administration of
nicotinamide mononucleotide (a NAD
+ precursor) to mice
protects against high-fat diet–induced metabolic disor-
ders. Bai et al. (6) obtained similar results using PARP1
knockout mice. Taken together, the evidence shows that
pharmacological interventions that increase NAD
+ are
a promising avenue for treating metabolic disorders.
However, the mechanism by which cellular NAD
+ is in-
creased may have different long-term outcomes. We fol-
lowed survival of wild-type, CD38 knockout, and PARP1
knockout mice fed a high-fat diet. Preliminary studies with
small numbers of mice suggest that CD38 knockout mice
have increased average and maximum life span compared
with wild-type mice when they are fed a high-fat diet.
However, in the PARP1 knockout mice, which also have
increased cellular NAD
+ levels (6), the outcome was oppo-
site this (Supplementary Fig. 2), with the PARP1 knockout
mice having a decreased life span compared with the wild-
type mice. This difference in survival could be explained by
the fact that PARP1 is involved in genomic stability (37) and
DNA repair both in the nucleus (37) and in mitochondria
(38,39). This suggests that although CD38 and PARP1
knockout mice have similar protection against metabolic
disorders, they may have distinct effects on longevity.
Here, we describe for the ﬁrst time that the ﬂavonoid
apigenin is a CD38 inhibitor, and both apigenin and quer-
cetin promote changes in intracellular NAD
+ levels. This
increase in NAD
+ levels leads to changes in protein acet-
ylation likely due to an increase in sirtuin activity. Fur-
thermore, we show that apigenin improves glucose
homeostasis and reduces lipid content in the liver in a
model of high-fat diet–induced obesity. Our results suggest
that lipid oxidation is increased by a SIRT1-dependent
mechanism. However, it could also happen that fatty acid
synthesis or export is altered, since SIRT1 has been shown
to regulate both processes (40,41). Our results demon-
strate that CD38 is a promising pharmacological target to
promote sirtuin actions and to treat metabolic diseases.
Flavonoids, including apigenin and quercetin, have
broad beneﬁcial effects (20). These two ﬂavonoids ame-
liorate atherosclerosis in mouse genetic models (25). Al-
though some of the beneﬁcial effects of ﬂavonoids on
metabolism are believed to be AMPK mediated (25), this
has not been clearly elucidated. Indeed, apigenin is a very
weak AMPK activator in vivo (25), which suggests an ad-
ditional mechanism of action. Our ﬁndings provide mech-
anistic evidence that ﬂavonoids can promote an increase
in NAD
+ levels through inhibition of CD38, resulting in
changes in protein acetylation, most likely through stimu-
lation of SIRT1 (Fig. 8D). Although we show here that
CD38 inhibition affects SIRT1 activity, it is likely that other
sirtuins will also be stimulated by CD38 inhibition. In-
terestingly, CD38 is also present and active in the mito-
chondria (42,43), where it may regulate mitochondrial
NAD
+ levels and mitochondrial sirtuin activity.
It is likely that, similar to what happens with many other
natural compounds, apigenin and quercetin have other
cellular targets besides CD38. However, we clearly show
that the increase in cellular NAD
+ levels promoted by
these compounds depends on CD38. More importantly, our
ﬁndings support the idea that pharmacological inhibition
of CD38 can be achieved as a strategy to treat obesity and
obesity-related diseases. Further research will help to de-
velop highly selective CD38 inhibitors that may be used as
an approach to treat metabolic syndrome in humans.
FIG. 7. CD38 inhibition by apigenin improves glucose homeostasis in vivo and improves lipid metabolism in the liver. Mice were fed a high-fat diet
(HFD) for 4 weeks and then split in two groups. One group was injected with apigenin (100 mg/kg i.p.) and the other with vehicle (DMSO) with
a single dose daily for 1 week. A: Blood glucose levels were measured during the week of apigenin treatment in ad libitum feeding conditions (*P <
0.05, n = 6 per group). ●, HFD; ■, HFD plus apigenin. B: Blood glucose levels were measured after 24 h of fasting on day 7 of treatment with
apigenin (*P < 0.05, n = 6 per group). C: Glucose tolerance test in mice after 7 days of treatment with apigenin (■) or vehicle (●)( * P < 0.05, n =6
per group). D: Area under the curve (AUC) calculated for the glucose tolerance test shown in C. ■, HFD; □, HFD plus apigenin.
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